Tirzepatide
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Phase 2 · Completed · Enrollment 367
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| LY3841136 Dose 1 | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 | n/r | n/r | n/r | n/r |
| LY3841136 Dose 3 | n/r | n/r | n/r | n/r |
| LY3841136 Dose 1 + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r |
| LY3841136 Dose 3 + Tirzepatide Dose 3 | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 3 | n/r | n/r | n/r | n/r |
| LY3841136 Dose 2 + Tirzepatide Dose 3 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- LY3841136 Dose 1: endpoint not reported
- LY3841136 Dose 2: endpoint not reported
- LY3841136 Dose 3: endpoint not reported
- LY3841136 Dose 1 + Tirzepatide Dose 1: endpoint not reported
- LY3841136 Dose 2 + Tirzepatide Dose 1: endpoint not reported
- LY3841136 Dose 2 + Tirzepatide Dose 2: endpoint not reported
- LY3841136 Dose 3 + Tirzepatide Dose 3: endpoint not reported
- Tirzepatide Dose 3: endpoint not reported
- LY3841136 Dose 2 + Tirzepatide Dose 3: endpoint not reported
- Placebo: endpoint not reported